NEWS
CONFERENCES
MEDIA
PUBLICATIONS
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
SUBSCRIBE

Opinion|Videos|December 21, 2023

NSCLC: Dato-DXd Combination Therapy

Author(s)Anne S. Tsao, MD, Edward B. Garon, MD, MS

Expert perspectives on clinical trials investigating doublet and triplet therapy with datopotamab deruxtecan in patients with non–small cell lung cancer.

Episodes in this series

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 1 Overview of Non–Small Cell Lung Cancer

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 2 The Role of Biomarkers in NSCLC Treatment

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 3 NSCLC Treatment: Unmet Needs and Antibody-Drug Conjugates

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 4 The Role of TROP2 as a Biomarker in NSCLC

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 5 NSCLC: Preclinical Studies on TROP2 Expression

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 6 Lung Cancer Treatment: Antibody-Drug Conjugates

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 7 Clinical Trial Data on Sacituzumab Govitecan in NSCLC

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 8 EVOKE-02: Sacituzumab Govitecan Plus Pembrolizumab in First-Line Metastatic NSCLC

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 9 Advanced NSCLC: TROPION-Lung02 and TROPION-Lung04

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 10 Antibody-Drug Conjugate Safety Profiles in NSCLC

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 11 Recent Data on Datopotamab Deruxtecan in NSCLC

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 12 NSCLC: Dato-DXd Combination Therapy

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 13 NSCLC: Role of ADCs and Ongoing EVOKE-01 and EVOKE-03 Studies

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 14 Progress and Unmet Needs in NSCLC Treatment

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 15 Future Targeted Therapy Approaches in NSCLC

Newsletter

Stay up to date on practice-changing data in community practice.

Related Content

CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC

ByTargeted Oncology Staff

July 20th 2026

Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC

BySabrina Serani

July 20th 2026

Sac-TMT Plus Pembrolizumab Beats Chemo-Immunotherapy in PD-L1–Negative NSCLC

BySabrina Serani

July 15th 2026

ROS1+ NSCLC: Key Takeaways From Case-Based Roundtables With Dr Santos

ByEdgardo Santos Castillero, MD, FACP, FASCO

July 15th 2026

FDA Grants Traditional Approval to Selpercatinib for RET Fusion–Positive Tumors

BySabrina Serani

July 14th 2026

Latest CME

Rhode Island Oncology Society

Rhode Island Oncology Society

3 Sessions are Available!

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Minnesota Society of Clinical Oncology

Minnesota Society of Clinical Oncology

2 Sessions are Available!

South Carolina Oncology Society

South Carolina Oncology Society

2 Sessions are Available!

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Kansas Society of Clinical Oncology

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Kansas Society of Clinical Oncology

Aditya Bardia, MD, MPH, FASCO; Bachar Samra, MD

Breaking Down the Rationale for Targeting TROP2 in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Establishing the Rationale for ADC and ICI Combinations in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

Sara A. Hurvitz, MD, FACP; Shaina Rozell, MD, MPH

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Kamel Abou Hussein, MD

Washington State Medical Oncology Society

Washington State Medical Oncology Society

1 Session is Available!

24th Annual International Congress on the Future of Breast Cancer® East

24th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Nevada Oncology Society

Nevada Oncology Society

3 Sessions are Available!

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

9th Annual School of Nursing Oncology™

9th Annual School of Nursing Oncology™

Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO; Beth Sandy, MSN, CRNP, FAPO; Lindsay Adkins, MSN, FNP-BC, BMTCN; Jeneth Aquino, DNP, FNP-BC; Casey Gormley, MSN, FNP-C, AOCNP; Heather J. Jackson, PhD, FNP-BC; Kelsey Martin, AG-ACNP-BC, AOCNP; Nerina T. McDonald, PA-C; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Faith A. Mutale, DNP, CRNP; Tiffany Richards, PhD, ANP-BC, AOCNP; Emily Skotte, DNP, MSN, ACNP-BC; Leslie Smith, DNP, RN, APRN-CNS, AOCNS, BMTCN; Saneese Stephen, PA-C, MPAS; Sara M. Tinsley-Vance, PhD, APRN, AOCN

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Seth A. Wander, MD, PhD; Marla D. Lipsyc-Sharf, MD

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Sara A. Hurvitz, MD, FACP; Rena Callahan, MD; Michelle Melisko, MD; Paolo Tarantino, MD, PhD

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

William J. Gradishar, MD, FASCO, FACP; Stephanie L. Graff, MD, FACP, FASCO; Cynthia X. Ma, MD, PhD

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Hope S. Rugo, MD; Alison K. Conlin, MD; Marleen Kok, MD, PhD; Heather McArthur, MD, MPH

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Erika P. Hamilton, MD; Giuseppe Curigliano, MD, PhD; VK Gadi, MD, PhD; Jason Aboudi Mouabbi, MD

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Tiffany A. Traina, MD, FASCO; Kevin Kalinsky, MD MS, FASCO; Mark E. Robson, MD, FASCO; Rebecca Shatsky, MD

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma

De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival

Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up

Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC

CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC